Tuesday, July 19, 2005

Glaxo plans to withdraw non-profitable drugs

Glaxo Smithkline (GSK) one of the leading brands in life saving drug making in both India as well International market is streamlining its product portfolio in a bid to weed out unprofitable brands. The latest brand to disappear from its product basket is antibiotic Furadantine. The drug maker is expected to focus on high value products in the product patent regime. It is expected that with this descision of Glaxo Smithkline of withdrawal the rival brand Ranbaxy will be gaining . Gramoneg by Ranbaxy is the only substitute for this drug. The drug is used for postoperative urinary tract infection, cystitis, pyelonephritis, pyelitis etc. Withdrawal of the particular drug brand can be attributed to the fact that the drug has become resistant to the organisms due to reasons ranging from incomplete dosage, drug not being used for proper indication under medical supervision and without being prescribed by an experienced physician.